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Objectives The goal of this analysis was to evaluate the association of impaired Thrombolysis In Myocardial Infarction myo-
cardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF).
Background Impaired TMPG after successful restoration of epicardial flow among patients treated with fibrinolytic therapy for
ST-segment elevation myocardial infarction (STEMI) has been associated with adverse clinical outcomes, but its
relationship to VT/VF has not been evaluated.
Methods In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction
28) study, 3,491 patients underwent angiography a median of 3.5 days after fibrinolytic administration for
STEMI; TMPG was assessed, and its association with VT/VF was evaluated.
Results We observed VT/VF in 4.8% of patients. Impaired myocardial perfusion (TMPG 0/1/2) was associated with an
increased incidence of VT/VF (7.1% vs. 2.6% with TMPG 3; log-rank p  0.001). Among patients with restoration
of normal epicardial flow (Thrombolysis In Myocardial Infarction flow grade 3), the incidence of VT/VF was in-
creased among patients with impaired TMPG (4.7% vs. 2.7%; p  0.02). Among patients with left ventricular
ejection fraction 30%, impaired TMPG remained associated with an increased incidence of VT/VF (4.7% vs.
2.5%; p  0.03). We found that VT/VF was associated with increased mortality (25.2% vs. 3.5%; p  0.0001).
Furthermore, among patients with VT/VF, impaired TMPG was associated with increased mortality (17.1% vs.
2.3%; p  0.02). All but 1 death among patients who had VT/VF were among patients with impaired myocardial
perfusion.
Conclusions Despite restoration of normal epicardial flow or a left ventricular ejection fraction 30%, impaired myocardial
perfusion on angiography 3.5 days after fibrinolytic administration for STEMI is associated with an increased in-
cidence of VT/VF. (J Am Coll Cardiol 2008;51:546–51) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.061(
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rne potentially fatal complication after ST-segment eleva-
ion myocardial infarction (STEMI) is ventricular tachyar-
hythmia, the most common cause of sudden cardiac death
rom the *TIMI Study Group, Beth Israel Deaconess Medical Center, Boston,
assachusetts; and †Brigham & Women’s Hospital and the ‡Division of Cardiology
nd Department of Medicine, Beth Israel Deaconess Medical Center, Harvard
edical School, Boston, Massachusetts. Supported in part by a grant from Sanofi-
ventis, Antony, France.a
Manuscript received June 18, 2007; revised manuscript received August 24, 2007,
ccepted August 27, 2007.SCD) (1). Approximately one-third to one-half of all
ardiac deaths after acute myocardial infarction (MI) have
een attributed to SCD (2). Identification of simply as-
essed clinical variables associated with subsequent ventric-
lar tachycardia (VT) and ventricular fibrillation (VF) could
rove useful in the triage of patients to more aggressive
harmacologic- or device-based therapies. Previous obser-
ational studies have demonstrated that traditional cardiac
isk factors, such as age, hypertension, and tobacco use, are
ssociated with an increased risk of VT/VF after MI (3–5).
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February 5, 2008:546–51 Impaired TMPG and Incidence of VT/VFn addition, impaired systolic function, prior episodes of
entricular arrhythmia, certain electrocardiographic find-
ngs, and the inducibility of arrhythmias on electrophysi-
logic studies are associated with future VT/VF (6).
Impairment of the Thrombolysis In Myocardial Infarc-
ion myocardial perfusion grade (TMPG) on coronary
ngiography has been associated with evidence of scar
evelopment, as imaged on magnetic resonance imaging
MRI) (7), poorer left ventricular (LV) function (8), in-
reased LV filling pressures (9), and a reduced salvage index
recovery of LV function) after MI (10). Given the associ-
tion of impaired TMPG with scar and reduced LV
unction, we hypothesized that impaired TMPG might be
ssociated with an increased risk of VT/VF. This hypothesis
as tested in the CLARITY-TIMI 28 (Clopidogrel as
djunctive Reperfusion Therapy–Thrombolysis in Myocar-
ial Infarction 28) study, in which patients presenting with
TEMI underwent angiography a median of 3.5 days after
brinolytic administration (11).
ethods
he CLARITY-TIMI 28 study was a multicenter, inter-
ational, randomized, double-blind, placebo-controlled trial
f aspirin versus aspirin plus clopidogrel in 3,491 patients
ho were treated with fibrinolytic therapy for STEMI (11).
n brief, patients were 18 to 75 years of age, presented
ithin 12 h of the onset of STEMI, and were scheduled to
ndergo coronary angiography 2 to 8 days after randomiza-
ion. When clinically indicated, patients underwent earlier
ngiography. Patients underwent percutaneous coronary
ntervention (PCI) at the discretion of the treating physi-
ian. Episodes of VT/VF were recorded in patients through
eath, hospital discharge, or 30 days after randomization,
hichever occurred first. Telephone follow-up occurred at day
0 to assess for any interim clinical end points or adverse
vents, which were confirmed by means of the medical record.
nly episodes of sustained VT and VF were reported as
efined by the individual investigators.
ngiographic analysis. All angiograms were analyzed off-
ine and blinded to treatment assignment at a central core
aboratory. Flow and perfusion in the infarct-related artery
ere evaluated using the Thrombolysis In Myocardial
nfarction flow grade (TFG) and TMPG. A single author
C.M.G.) evaluated TMPG. The intraobserver (92.5%) and
nterobserver (85.0%) agreement of TMPG have been
eported to be high (12). Ventriculography was performed
t the discretion of the physician.
tatistical analysis. All analyses were performed with Stata
ersion 9.2 (College Station, Texas). All continuous vari-
bles are reported as the median and interquartile range and
ere tested using the nonparametric Wilcoxon rank-sum
est. The chi-square test or Fisher exact test was used for the
nalysis of categorical variables when appropriate.
Cox proportional-hazards regression and Kaplan-
eier survival analysis were used to evaluate associa-ions with VT/VF. Incidence
ates of VT/VF are reported
ith Kaplan-Meier hazard rates
hrough discharge or 30 days.
he proportional-hazards as-
umption was tested before
unning the Cox models, and
ime-varying covariates were
dded as needed.
Analyses of VT/VF and sub-
equent mortality are reported as
valuated in the context of a model
n which VT/VF was modeled as
time-variant covariate of mor-
ality. Associations between
T/VF as a time-invariant co-
ariate of mortality also were
valuated; where these results are
iscordant with those with time-
arying covariates, they are noted
n the text.
esults
aseline characteristics. Patients underwent angiography
median of 3.5 days after randomization (interquartile
ange 2.1 to 5.2). There were a total of 180 VT/VF events
mong 167 patients (Fig. 1). Patients with VT/VF were
ore often of nonwhite race, of lower body weight, and
ore often had sustained a previous MI and an anterior MI;
hey were less likely to have been administered beta-
lockers, statins, angiotensin-converting enzyme inhibitors
r angiotensin-receptor blockers, or low-molecular-weight
eparin (Table 1).
linical outcomes. Impaired TMPG was associated with
n increased incidence of VT/VF (hazard ratio [HR] 2.4,
5% confidence interval [CI] 1.68 to 3.54, p  0.01)
Figure 1 Consort Diagram
Flow chart of patients used in the analysis.
VF  ventricular fibrillation; VT  ventricular tachycardia.
Abbreviations
and Acronyms
MRI  magnetic resonance
imaging
PCI  percutaneous
coronary intervention
SCD  sudden cardiac
death
STEMI  ST-segment
elevation myocardial
infarction
TFG  Thrombolysis In
Myocardial Infarction flow
grade
TMPG  Thrombolysis In
Myocardial Infarction
myocardial perfusion grade
VF  ventricular fibrillation
VT  ventricular
tachycardia
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Impaired TMPG and Incidence of VT/VF February 5, 2008:546–51Fig. 2). Among patients with TFG 3 at angiography,
hose with impaired TMPG had a greater incidence of
T/VF (HR 1.8, 95% CI 1.13 to 2.90; p  0.01) (Fig.
A). In addition, among patients with normal to mod-
rately reduced systolic function (left ventricular ejection
raction [LVEF] 30%) at angiography, TMPG 0/1/2
as associated with an increased incidence of VT/VF
HR 1.9, 95% CI 1.04 to 3.36; p  0.04) (Fig. 3B).
mpaired myocardial perfusion was associated with both
n increased incidence of having had VT/VF before
ngiography and having VT/VF after angiography, even
mong patients with patent infarct-related arteries (TFG
Baseline Characteristics
Table 1 Baseline Characteristics
Characteristic VT/VF* (n
Clopidogrel 75 mg treatment
assigned: n/N (%)
87/167
Age, yrs
Median 58
Interquartile range 51–
Male gender, n/N (%) 126/167
White race, n/N (%) 141/167
Weight, kg
Median 77
Interquartile range 68–
Hypertension, n/N (%) 75/165
Hyperlipidemia, n/N (%) 56/142
Current smoker, n/N (%) 90/167
Diabetes mellitus, n/N (%) 26/161
Previous MI, n/N (%) 23/166
Previous PCI, n/N (%) 8/166
Anterior MI, n/N (%) 81/167
Fibrinolytic agent, n/N (%)
Tenecteplase 78/167
Reteplase 11/167
Alteplase 15/167
Streptokinase 63/167
Reteplase  streptokinase 0/167
None 0/167
Initial aspirin, n/N (%) 162/167
Initial heparin, n/N (%)
Unfractionated heparin 73/167
Low-molecular-weight heparin 40/167
Both 14/167
Neither 40/167
Time from symptom onset to start of
fibrinolytic therapy, h
Median 2
Interquartile range 1.7–
Cardiac medications during index
hospitalization, n/N (%)
Beta-blockers 131/167
Statins 113/167
ACE inhibitors or angiotensin-
receptor blockers
109/167
Only first VT/VF event was evaluated per patient from randomization th
patients had VT/VF at times that were inevaluable relative to time of an
ACE  angiotensin-converting enzyme; MI  myocardial infarction;
ventricular tachycardia.or 3) (Figs. 4 and 5). lPatients who underwent PCI during the index hospital-
zation had the same incidence of VT/VF as those who did
ot (Fig. 6A). However, of those undergoing PCI, patients
ith poor myocardial perfusion both before and after PCI
ad a greater incidence of VT/VF after PCI than those who
ad normal myocardial perfusion either before PCI, after
CI, or at both times (Fig. 6B). Patients with TMPG 3
oth before and after PCI had a lower incidence of VT/VF
fter PCI when compared with those who had impaired
yocardial perfusion before PCI, after PCI, or at both
imes (0.2% vs. 7.9%; log-rank p  0.03).
Despite the fact that patients without VT/VF were more
7) No VT/VF (n  3,324) p Value
) 1,665/3,324 (50.1) 0.613
0.557
58
50–66
) 2,677/3,324 (80.5) 0.107
) 2,984/3,324 (89.8) 0.028
0.042
80
70–89
) 1,439/3,286 (43.8) 0.674
) 1,082/2,810 (38.5) 0.824
) 1,662/3,317 (50.1) 0.340
) 549/3,274 (16.8) 0.837
) 295/3,304 (8.9) 0.032
161/3,312 (4.9) 0.980
) 1,338/3,324 (40.3) 0.034
0.187
) 1,582/3,324 (47.6)
411/3,324 (12.4)
299/3,324 (9.0)
) 1,021/3,324 (30.7)
1/3,324 (0.03)
10/3,324 (0.30)
) 3,279/3,324 (98.7) 0.082
0.050
) 1,527/3,324 (45.9)
) 994/3,324 (29.9)
161/3,324 (4.8)
) 642/3,324 (19.3)
0.113
2.7
1.75–4.15
) 2,982/3,324 (89.7) 0.001
) 2,705/3,324 (81.4) 0.001
) 2,418/3,324 (72.7) 0.035
ospital discharge, death, or day 30 (whichever occurred first). Eighteen
hy. *Twenty-nine patients had VT/VF but did not undergo angiography.
ercutaneous coronary intervention; VF  ventricular fibrillation; VT  16
(52.1
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(75.5
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February 5, 2008:546–51 Impaired TMPG and Incidence of VT/VFngiotensin-converting enzyme inhibitors/angiotensin re-
eptor blockers, multivariate analysis revealed that the use of
hese medications was not associated with the incidence of
T/VF, nor did they alter the point estimates for the
elationship between TMPG and VT/VF. Multivariate
nalysis did not reveal any association between clopidogrel
dministration and the incidence of VT/VF, nor did it alter
he point estimates for the relationship between TMPG and
T/VF. In addition, although anterior MI was associated
Figure 2 VT/VF Among Patients With
TMPG 0/1/2 Compared With TMPG 3
Impaired myocardial perfusion at angiography was associated with a signifi-
cantly greater incidence of ventricular tachycardia (VT) or ventricular fibrilla-
tion (VF). TMPG  Thrombolysis In Myocardial Infarction myocardial
perfusion grade.
Figure 3 VT/VF Among Subgroups
Even among patients with normal epicardial flow (Thrombolysis In Myocardial
Infarction flow grade 3), impaired myocardial perfusion was associated with a
significantly greater incidence of VT/VF than normal perfusion (A). Similarly,
among patients with relatively preserved systolic function (left ventricular ejec-
tion fraction 35%), impaired myocardial perfusion was associated with an
increased incidence of VT/VF (B). Abbreviations as in Figure 2.iith a trend toward a greater incidence of VT/VF, after
djusting for this, the association between impaired TMPG
nd VT/VF remained significant.
We found that VT/VF at any point during hospitaliza-
ion was associated with increased mortality at 30 days
25.9% vs. 3.5%; log-rank p  0.0001). Most patients with
T/VF died of SCD. We also found that VT/VF in the
ontext of TMPG 0/1/2 was associated with increased
ortality when compared with its occurrence in the pres-
nce of normal TMPG (17.5% vs. 2.4%; log-rank p 
.02). All but 1 death among patients who had VT/VF were
mong patients with impaired myocardial perfusion. Fur-
hermore, among patients with TFG 3 at angiography, all
atal VT/VF was observed among patients with TMPG
/1/2.
iscussion
his analysis demonstrates that among STEMI patients
reated with fibrinolytic therapy, impaired myocardial per-
usion on coronary angiography, as assessed by TMPG, is
ssociated with an increased incidence of VT/VF. Further-
ore, among patients with successful restoration of TFG 3,
hose with impaired myocardial perfusion had an 80%
reater risk of VT/VF. Even among patients with an LVEF
30%, the presence of impaired myocardial perfusion was
ssociated with a nearly 2-fold greater incidence of VT/VF.
The prognosis of VT/VF varied depending upon myo-
ardial perfusion. We found that VT/VF, in the context of
Figure 4 VT/VF Before and After Angiography
Poor myocardial perfusion was associated with a significantly greater incidence
of VT/VF before (A) and after angiography (B). Abbreviations as in Figure 2.mpaired myocardial perfusion (TMPG 0/1/2), was associ-
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Impaired TMPG and Incidence of VT/VF February 5, 2008:546–51ted with increased mortality when compared with its
ccurrence in the presence of normal TMPG 3. Indeed, all
ut 1 death among patients who had VT/VF were among
atients with impaired TMPG.
It could be speculated that VT/VF in the context of
ormal perfusion represents a “reperfusion arrhythmia” and
eflects successful restoration of epicardial patency, whereas
T/VF in the context of impaired perfusion may be the
esult of capillary plugging, edema, capillary leak, or scar. In
ddition, the increased incidence of malignant arrhythmia
mong patients with impaired myocardial perfusion could
xplain the previous observation of poorer survival among
atients with TFG 3 who had impaired TMPG (13).
Most SCDs are caused by ventricular tachyarrhythmias
1). Approximately 65% of patients who experience SCD
ave underlying coronary artery disease (14). Abnormal
yocardial perfusion among patients with VT/VF in the
resent analysis is consistent with SCD autopsy studies that
emonstrate impaired myocardial perfusion on postmortem
ngiography (15,16).
The most plausible pathophysiologic mechanisms under-
ying the observations in the present analysis are the
reviously described association of impaired perfusion with
ngoing ischemia, microvascular obstruction, edema, scar
ormation, and hyperenhancement on cardiac MRI, each of
hich are, in turn, associated with VT/VF (2,7,17–
Figure 5 VT/VF Before and After Angiography
Among Patients With Preserved Epicardial Flow
Among patients with an open artery at angiography (Thrombolysis In Myocardial
Infarction flow grade 2 or 3), impaired myocardial perfusion was associated
with a significantly greater incidence of VT/VF both before (A) and after angiog-
raphy (B). Abbreviations as in Figure 2.2). Alternatively, local metabolic derangements (23) asell as changes in the expression of cardiomyocyte
embrane ion channels, could be induced by poor
yocardial perfusion (24).
A number of epidemiologic risk factors associated with
entricular arrhythmia have been observed (3–5). Risk factor
ssessment is ever-changing as modern pharmacologic ther-
py for coronary artery disease and heart failure change (25).
ttempts at SCD risk stratification have been made (6), taking
nto account noninvasive and invasive studies, including echo-
ardiographic measurement of LVEF and electrocardiographic
nd electrophysiologic data. The ability of the TMPG to
rovide incremental discriminatory power to sudden death risk
tratification tools warrants further evaluation.
tudy limitations. This analysis is a nonrandomized ret-
ospective one and, as such, it is possible that both identified
nd unidentified confounders may have influenced the
utcomes. Episodes of VT/VF were not prespecified as
utcomes in the study, and individual investigators defined
T/VF rather than a core laboratory. Angiographic data
ere not available in those patients who died before angiog-
aphy. Left ventricular function was not assessed in all
atients. Follow-up from hospital discharge through 30
ays was by report only, and there may have been
ncidences of VT/VF during this time period that were
eported as deaths alone if there was no documentation of
fatal ventricular arrhythmia, thus possibly underesti-
ating the incidence of VT/VF during this time. Al-
Figure 6 VT/VF Among Patients Undergoing PCI
No significant differences were found in the incidence of VT/VF among patients
who underwent percutaneous coronary intervention (PCI) compared with those
who did not (A). Normal perfusion before, after, or both before and after PCI
was associated with a significantly lower incidence of VT/VF than poor perfu-
sion both before and after PCI (B). Abbreviations as in Figure 2.
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February 5, 2008:546–51 Impaired TMPG and Incidence of VT/VFhough the findings presented here are provocative,
ecause of the short-term follow-up and retrospective
ature of the results, therapeutic decisions regarding the
reatment of VT/VF should be based on prospective,
andomized studies.
onclusions
espite restoration of Thrombolysis In Myocardial Infarc-
ion grade 3 epicardial flow or an LVEF 30%, impaired
MPG at angiography 3.5 days after fibrinolytic adminis-
ration for STEMI is associated with an increased incidence
f VT/VF.
eprint requests and correspondence: Dr. C. Michael Gibson,
irector, TIMI Data Coordinating Center, 350 Longwood Ave-
ue, First Floor, Boston, Masschusetts 02115. E-mail: mgibson@
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